Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0B7NG
|
||||
Former ID |
DAP000336
|
||||
Drug Name |
Chlorpheniramine
|
||||
Synonyms |
Allergican; Allergisan; Antagonate; Chloropheniramine; Chlorophenylpyridamin; Chlorophenylpyridamine; Chloropiril; Chloroprophenpyridamine; Chlorphenamine; Chlorphenaminum; Chlorpheniraminum; Chlorprophenpyridamine; Clofeniramina; Clorfenamina; Clorfeniramina; Cloropiril; Haynon; Hayon; Histadur; ISOCLOR; Kloromin; Phenetron; PiriIton; Piriton; Polaronil; Telachlor; Teldrin; Chlorphenamine [INN]; Clorfeniramina [Italian]; Pediacare Allergy Formula; [3H]Chlorpheniramine; Aller-Chlor; Chlo-amine; Chlor-Pro; Chlor-Trimeton Repetabs; Chlor-trimeton; Chlorphenamine (INN); Chlorphenaminum [INN-Latin]; Clofeniramina (TN); Clorfenamina [INN-Spanish]; Comakin (TN); Gen-Allerate; Novo-Pheniram; Piriton (TN); Chlor-Trimeton (TN); Chlor-Tripolon (TN); CHLORPHENIRAMINE (SEE ALSO: CHLORPHENIRAMINE MALEATE (CAS113-92-8)); Gamma-(4-Chlorophenyl)-gamma-(2-pyridyl)propyldimethylamine; Gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine; 1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane; 2-(p-Chloro-alpha-(2-(dimethylamino)ethyl)benzyl)pyridine; 3-(4-chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; 3-(p-Chlorophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine; 4-Chloropheniramine
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiallergic Agents
|
||||
Company |
Schering-Plough Corporation
|
||||
Structure |
Download2D MOL |
||||
Formula |
C16H19ClN2
|
||||
InChI |
InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m1/s1
|
||||
InChIKey |
SOYKEARSMXGVTM-OAHLLOKOSA-N
|
||||
CAS Number |
CAS 132-22-9
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9299815, 11110931, 11110932, 11112256, 11363014, 11365576, 11368138, 11371329, 11373943, 11376300, 11484028, 11487972, 11490161, 11492097, 11493954, 15442268, 33774101, 47719847, 48018097, 50064683, 50100400, 50225325, 57304992, 85789162, 109896795, 135650086, 135774423, 137002507, 160666558, 174007153, 175269603, 179039539, 226396260
|
||||
ChEBI ID |
ChEBI:52010
|
||||
SuperDrug ATC ID |
R06AB04
|
||||
SuperDrug CAS ID |
cas=000132229
|
||||
Target and Pathway | |||||
Target(s) | Histamine H1 receptor | Target Info | Antagonist | [534934], [536700], [537884] | |
PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
References | |||||
Ref 538228 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070797. | ||||
Ref 542007 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6976). | ||||
Ref 534934 | Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol. 1999 Sep-Oct;13(5):391-9. | ||||
Ref 536700 | Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. Epub 2008 Apr 29. | ||||
Ref 537884 | Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Jan 1;266(1):99-102. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.